Articles

A rare tumour of the lacrimal gland: Immunoglobulin G4-related pseudo tumour

BJMO - volume 18, issue 1, february 2024

D. Schrijvers MD, PhD, L. Velthof MD, K. De Boeck MD, M. Al Saddi MD, V. De Groot MD, PhD

SUMMARY

This case report describes a patient with a lacrimal tumour and distant bone lesions. The diagnosis of an IgG4-related pseudo tumour of the lacrimal gland with involvement of the skeleton was made. A review of lacrimal gland lesions and IgG4-related disease is given. The oncologist should be aware of this entity and it should be included in the differential diagnosis of lacrimal gland lesions.

(Belg J Med Oncol 2024;18(1):24–8)

Read more

A subungual glomus tumour in a patient with a previous history of testicular cancer

BJMO - volume 17, issue 7, november 2023

M. De Wit MD, L-A-F. Clifton MD, E. Beuckelaers MD, J. Desimpelaere MD, D. Schrijvers MD, PhD

SUMMARY

This article presents the case of a 35-year-old patient with a glomus tumour in the fourth digit of the right hand. The patient had a history of a bilateral embryonal testicular carcinoma, which was treated with surgery and chemotherapy. The initial complaints consisted of pain in all the fingers on the right hand, suspected of Raynaud phenomenon. Finally, the diagnosis was made clinically and through magnetic resonance imaging. He underwent surgery to remove the tumour, and the diagnosis was pathologically confirmed. The treatment was curative, and the complaint of pain resolved.

(Belg J Med Oncol 2023;17(7):264–6)

Read more

Burnout in resident physicians

BJMO - volume 17, issue 3, may 2023

D. Schrijvers MD, PhD

SUMMARY

Burnout is an important consequence of work-related stress. It is observed in 15–40% of resident physicians and has an important influence on their wellbeing, their professional career, and their patient-doctor relationship. Different interventions at the organisational, interpersonal and personal levels can be performed to prevent the development of burnout.

(BELG J MED ONCOL 2023;17(3):85–7)

Read more

Head and neck cancer: The role of cisplatin

BJMO - volume 17, issue 2, march 2023

D. Schrijvers MD, PhD

SUMMARY

Cisplatin has been the backbone of the treatment of patients with squamous cell carcinoma of the head and neck, both in recurrent/metastatic settings and in patients with locoregional disease. In patients with recurrent/metastatic disease and a combined positivity score (CPS) ≥20, cisplatin can be replaced by pembrolizumab. In patients with locoregional disease and treated with definitive chemoradiation or in the adjuvant setting, the 3-weekly high-dose cisplatin can be replaced by the weekly 40 mg/m2 cisplatin regimen.

(Belg J Med Oncol 2023;17(2):52–7)

Read more

Audits in medical oncology

BJMO - volume 17, issue 1, january 2023

D. Schrijvers MD, PhD

SUMMARY

The quality of oncological care can be ensured by different means, such as graduate and postgraduate education, guidelines, quality labels and audits. Audits in medical oncology departments are not routinely performed and are only used in case of problems. In this article, the introduction of audits in the medical oncology department is advocated, and a strategy to implement this quality improving tool is proposed.

(BELG J MED ONCOL 2023;17(1):19–26)

Read more

What are the treatment options for metastatic castration-resistant prostate cancer anno 2023?

BJMO - volume 17, issue 1, january 2023

D. Schrijvers MD, PhD

SUMMARY

Patients developing metastatic castration-resistant prostate cancer are in most instances pre-treated with androgen deprivation treatment and a newer androgen receptor-targeting agent in the metastatic castration-sensitive setting.

In this article, I discuss the first- and second-line treatment options in this patient population.

(BELG J MED ONCOL 2023;17(1):15–8)

Read more

The benefit of anticancer drugs

BJMO - volume 16, issue 7, november 2022

D. Schrijvers MD, PhD

SUMMARY

New anticancer drugs are continuously developed and show statistically significant differences compared to the standard treatment. However, their clinical impact is not always shown. In this review, two systems to evaluate the meaningful clinical benefit are discussed: the ESMO-MCBS, developed by ESMO, and the ASCO value framework, proposed by ASCO. Both systems evaluate clinical meaningful effects of new anticancer drugs based on available clinical research, and grade them according to the system they developed. Whereas the ESMO-MCBS is a tool directed to guide development and health care system professionals, the ASCO value framework is a tool to help the medical oncologist and the patient to make an informed decision in relation to the value of a new treatment, including costs.

(BELG J MED ONCOL 2022;16(7):355–9)

Read more